MedCity News May 15, 2022
Robert Fallon

Government-funded initiatives such as the Cancer Moonshot support not only the primary science that often serves as a foundation for medical advances, but also ensure that patients with rare cancers are not overlooked.

I’ve been a big fan of the Cancer Moonshot since President Biden first championed the initiative when he was serving as Vice President under President Obama. I previously shared my personal experience talking with him about it when I serendipitously bumped into him on the Acela train, and he was gracious enough to have a conversation with me about the future of cancer care and research.

Last month, President Biden announced the reigniting of the Cancer Moonshot. The reinvigorated effort shares goals of the original initiative in...

Today's Sponsors

SalesSparx
Canton & Company
Curation Health

Today's Sponsors

Amwell
Oliver Wyman

Today's Sponsor

Canton & Company

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
FDA guidance on patient-focused drug development
Lifesciences, healthcare VC firm closes $525M investment fund
The post-Covid New Normal: a golden opportunity for the NHS?
10 clinical trials to watch in the second half of 2022
Two cancer biotechs merge, raise cash as sector-wide downturn continues